Global Trigeminal Neuralgia Treatment Medicine Market Size, Share And Trends Analysis Report, By Type (Anticonvulsants, Antispasmodic Agents And Botox Injections), By End User (Hospital, Clinic, And Others ), Forecast (2022-2028)

The trigeminal neuralgia treatment medicine market is anticipated to grow at a significant CAGR of 6.0%  during the forecast period (2022-2028). Trigeminal neuralgia is a condition in which on one side of the face, pain sensations similar to an electric shock are experienced. This is a chronic condition that appears from time to time.  The trigeminal nerve is affected in this condition and pain sensations travel from the face to the brain. In the case of trigeminal neuralgia, minimal movement or touching of the face parts such as brushing teeth or doing makeup can trigger unbearable pain shock on the face. In conditions, initially, there are mild attacks but after some time, the time and frequency of the pain shock increase.  trigeminal neuralgia is mostly seen in the geriatric population. This condition can be effectively managed by medications and surgery. As per National Center for Biotechnology Information in the United States, the prevalence rate of trigeminal neuralgia is 4 to 13 per 100000 people.

 

 

The global trigeminal neuralgia treatment medicine market is segmented by type and by end-user. Based on type, the market is sub-segmented into anticonvulsants, antispasmodic agents, and botox injections. Based on end-user, the market is sub-segmented into hospitals, clinics, and others. Anticonvulsants such as carbamazepine (Tegretol, Carbatrol, others) are prescribed by health experts in the treatment of trigeminal neuralgia and these have proved effective in treating chronic pain which lasts longer than a month. Some other anticonvulsants which are prescribed in trigeminal neuralgia are oxcarbazepine (Trileptal, Oxtellar XR).

 

 

Some major players in the market include Novartis AG, Allergen Plc, GlaxoSmithKline Plc, Abbott Laboratories. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in Feb 2022, Noema Pharma has announced that it has started the clinical trial of  mGluR5 inhibitor NOE-101. This drug would be used to treat trigeminal neuralgia. According to the company it has tested this drug on the first patient enrolled for this trial. NOE-101 is an allosteric modulator of mGlu5 and is highly selective and potent. The clinical trial which is associated with this drug is named as Phase IIb LibraTN study.

 

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Novartis AG, Allergen Plc, GlaxoSmithKline Plc,Abbott Laboratories.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Trigeminal Neuralgia Treatment Medicine Market Report By Segment

By Type

• Anticonvulsants
• Antispasmodic Agents
• Botox Injections

By End-User

• Hospital
• Clinic
• Others

 

Trigeminal Neuralgia Treatment Medicine Market Report By Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa